SEC Form 4 · accession 0001179110-15-003036
MOMENTA PHARMACEUTICALS INC · MNTA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael Franken
Officer — President, Biosimilars Busines
Period of report
Feb 18, 2015
Accepted (ET)
Feb 20, 2015 · 3:04 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001235010
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Feb 18, 2015 | A | 16,976 | $0.00 | A | 40,025 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to buy)F3 | $13.02 | Feb 18, 2015 | A | 33,953 | A | May 18, 2015 | Feb 18, 2025 | Common Stock | 33,953 | 103,953 | D |
Explanation of responses
- F1Represents 16,976 shares of restricted common stock, $0.0001 par value per share, awarded pursuant to the Company's 2013 Stock Incentive Plan, and subject to a restricted stock agreement to be entered between the Company and Mr. Franken. Pursuant to the restricted stock agreement, 25% of the shares of restricted Common Stock shall vest on February 18, 2016 and an additional 6.25% of the shares of restricted Common Stock shall vest at the end of each three-month period thereafter.
- F2This balance of shares beneficially owned reflects 96 shares acquired under the employee stock plan at a purchase price of $9.10 per share on January 31, 2015.
- F3Represents an option granted by the issuer pursuant to the issuer's 2013 Stock Incentive Plan. Subject to certain criteria, the shares subject to such option vest as to 6.25% of the shares at the end of each three-month period following the grant date